Managing GLP-1 Side Effects: Nausea, Fatigue, and 'Sulfur Burps

GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda) — are among the most effective obesity and diabetes medications available. They're also known for a distinct set of gastrointestinal side effects that, for some people, are the deciding factor in whether they stay on treatment.

The good news: most of these side effects are predictable, manageable, and temporary. They're most intense during dose escalation and tend to diminish as your body adapts. Knowing what to expect — and having practical strategies ready — dramatically improves tolerability.

Why GLP-1s Cause GI Side Effects

The mechanism is tied directly to how these drugs work. GLP-1 receptors are found throughout the gastrointestinal tract. When a GLP-1 receptor agonist activates these receptors, it:

• Slows gastric emptying — food stays in your stomach longer, which is part of why you feel full faster but also contributes to nausea, reflux, and constipation
• Reduces gut motility — slowing the movement of contents through the intestine
• Acts on the brainstem's vomiting center (area postrema) — GLP-1 receptors are present in the nausea/vomiting control centers of the brain

This isn't a sign the medication is harming you. It's the mechanism of action, and it's why the titration schedule exists — slow dose increases allow these receptors to adapt gradually.

In the STEP 1 clinical trial of semaglutide, nausea was reported by 44% of participants, vomiting by 24%, diarrhea by 30%, and constipation by 24% at some point over 68 weeks. Most events were mild-to-moderate in severity. Discontinuation due to GI events occurred in about 4.5% of participants.

Nausea: The Most Common Complaint

What It Feels Like

Most people describe GLP-1 nausea as a persistent background queasiness rather than acute, acute stomach upset. It's often worse in the first day or two after injection and improves by the end of the week. At higher doses, it can be more intense.

Evidence-Based Strategies

1. Inject at night before bed Timing your injection for the evening means the peak plasma concentration — and peak nausea — occurs while you're asleep. Many clinicians and patients report this as the single most effective adjustment. There is no published head-to-head trial comparing morning vs. evening injection for nausea, but clinical experience strongly supports this approach.

2. Eat smaller, more frequent meals A full stomach on top of slowed gastric emptying is a reliable nausea trigger. Aim for 3–4 small meals rather than 2–3 large ones. Keep portions to roughly half what you'd normally eat. Eating slowly and stopping before you feel "full" (rather than after) reduces post-meal nausea significantly.

3. Avoid high-fat and high-sugar meals post-injection Fat slows gastric emptying independently of GLP-1 medication. Eating a fatty meal when your stomach is already emptying more slowly is a recipe for prolonged nausea. Similarly, large sugar loads can worsen GI symptoms. Lean proteins, cooked vegetables, and plain starches (rice, oats) are easier on the system during adjustment.

4. Stay hydrated Dehydration worsens nausea. Aim for at least 64 oz of water daily. Sipping slowly throughout the day is better tolerated than drinking large amounts at once. Electrolyte beverages without high sugar content (like Liquid IV or plain coconut water) can help if you've been vomiting.

5. Ginger Ginger has robust evidence for nausea reduction across multiple contexts (pregnancy, chemotherapy, motion sickness). A 2014 systematic review in Nutrition Journal found ginger significantly reduces nausea scores. Ginger tea, ginger chews, or ginger capsules (500–1000 mg) before meals may help.

6. Ask about anti-nausea medication If nausea is significantly impacting your quality of life or food intake, speak with your provider. Ondansetron (Zofran), typically used for chemotherapy nausea, is sometimes prescribed short-term for GLP-1 users. Promethazine is another option. These are not routinely necessary but are legitimate tools for patients who struggle during dose escalation.

Sulfur Burps: The Side Effect Nobody Talks About (Until It Happens to Them)

What They Are

"Sulfur burps" — belching with a rotten egg or sulfur smell — are one of the most unpleasant and least-discussed side effects of GLP-1 medications. They occur because slowed gastric emptying means food sits in the stomach longer, fermenting and producing hydrogen sulfide gas. This gas, when released via belching, has a distinctive rotten-egg odor.

They're not a sign of infection or disease. But they can be socially distressing and indicate your GI system is working especially slowly.

Managing Sulfur Burps

• Eat smaller portions, more slowly: Less food in the stomach means less fermentation opportunity.
• Avoid sulfur-rich foods during dose escalation: Eggs, red meat, cruciferous vegetables (broccoli, cauliflower, cabbage), and dairy all contain sulfur compounds. Temporarily reducing these — especially on injection days — can help.
• Avoid carbonated beverages: Carbonation adds gas on top of GI gas, worsening the problem.
• Simethicone (Gas-X): An OTC gas-relief medication. Simethicone breaks up gas bubbles in the stomach and can reduce burping. It's not absorbed systemically, so it's safe to use alongside GLP-1 medication.
• Pepcid (famotidine): Some users find an OTC H2 blocker helps with both reflux and the frequency of burping. Ask your provider if this seems warranted.
• Bismuth subsalicylate (Pepto-Bismol): Bismuth is known to bind hydrogen sulfide and may reduce sulfur smell. Note that it contains aspirin-related compounds and should be used cautiously in people with aspirin sensitivity.

Constipation: The Slow-Motion Problem

GLP-1-induced constipation is common and underreported, partly because people feel embarrassed discussing it. In the SURMOUNT-1 trial of tirzepatide, constipation was reported in 17% of participants on the 15 mg dose.

Slowed GI motility means stool spends more time in the colon, where more water is absorbed — resulting in harder, harder-to-pass stool.

Practical Solutions

• Increase fluid intake first. Most GLP-1-induced constipation responds well to hydration. Aim for 8–10 cups of water daily.
• Increase dietary fiber gradually. Soluble fiber (oats, psyllium, beans) adds bulk and draws water into stool. Insoluble fiber (vegetables, whole grains) speeds transit. Start slowly — increasing fiber too rapidly can cause cramping and gas.
• Psyllium husk (Metamucil): One of the most evidence-backed fiber supplements for constipation. Mix with plenty of water.
• Daily movement: Even a 20-minute walk can stimulate bowel motility. Physical activity promotes the gastrocolic reflex.
• Magnesium citrate: A gentle, osmotic laxative available OTC. 200–400 mg at bedtime is a common approach. Unlike stimulant laxatives, it doesn't cause dependency. Always check with your provider first, especially if you have kidney disease.
• Avoid stimulant laxatives as a first line: Senna and bisacodyl work but can cause dependence with regular use. Reserve for acute relief, not daily management.

Diarrhea and Loose Stools

Less commonly, GLP-1s cause the opposite problem — loose stools or diarrhea. This is more common early in treatment and usually self-resolves. If it persists:

• Eat a low-fat, low-fiber diet temporarily
• Avoid lactose and high-fructose foods
• Stay well hydrated with electrolyte-containing fluids
• OTC loperamide (Imodium) is safe for short-term use
• Persistent diarrhea lasting more than 2 weeks warrants a provider call

Fatigue

Fatigue during the early weeks of GLP-1 treatment usually has multiple contributing factors:

1. Reduced caloric intake — the body has less fuel
2. Lower carbohydrate intake — if your eating naturally shifts lower-carb, your energy may dip while adapting
3. Possible mild dehydration — from reduced food intake (food provides meaningful water)
4. The medication itself — some patients report tiredness that is not fully explained by intake changes

What Helps

• Ensure adequate protein and calories. Undereating is the most common culprit. If you're consistently below 1,000–1,200 kcal/day, fatigue is expected. Check your intake with a logging app, even briefly.
• Maintain carbohydrate intake at a reasonable level. Extreme low-carb eating on top of GLP-1-suppressed appetite can cause fatigue and brain fog. Unless advised by your provider, don't eliminate carbohydrates.
• Check labs. Fatigue can be a sign of anemia, thyroid dysfunction, or deficiencies in iron, B12, or vitamin D — all of which are common in people with obesity or metabolic disease, independent of medication. A comprehensive metabolic panel and CBC are worth requesting if fatigue persists beyond 4 weeks.
• Prioritize sleep. GLP-1 users often report improved sleep as weight loss progresses — but early on, disrupted sleep from GI discomfort can worsen fatigue.

When to Call Your Provider

Most side effects are manageable with lifestyle adjustments. However, some warrant prompt medical attention:

Symptom	Action
Severe, persistent abdominal pain (especially radiating to the back)	Call immediately — may indicate pancreatitis
Vomiting so frequent you can't keep liquids down	Seek care for dehydration/medication adjustment
Significant pain in upper right abdomen	Possible gallbladder issue (gallstones are a known GLP-1 risk)
Rapid heart rate, chest pain	Seek emergency care
Blood in stool	Call your provider

The FDA label for Ozempic lists acute pancreatitis as a warning, though it is rare. Gallbladder disease is also a noted risk, particularly with rapid weight loss.

A Note on Dose Pauses

If side effects are significantly impacting your ability to eat, drink, or function, contact your prescriber about pausing or slowing your dose escalation. There's no clinical disadvantage to staying at a lower dose for an extra 4 weeks. The STEP and SURMOUNT trials used standardized escalation schedules, but real-world prescribing allows flexibility. A slow titration schedule often leads to better long-term adherence.

Independent Analysis: What the Trial Safety Data Tells Us About Side-Effect Management

Three observations from the STEP and SURMOUNT safety data and GI pharmacology literature that change how to approach side effects practically:

1. The nausea timing curve predicts when to expect relief

Across the STEP trials, nausea incidence followed a consistent temporal pattern: peak incidence in the first 2 weeks after each dose escalation, with a return toward baseline by weeks 6–8 at a stable dose. This is not anecdote — it is the expected pharmacodynamic response to GLP-1-mediated slowing of gastric emptying as the gut adapts. The STEP 1 safety supplement shows that nausea-related discontinuation clustered in the first 20 weeks, almost entirely during active dose escalation periods. The practical implication for patients is that nausea at a new dose should be evaluated against the expected timeline: if nausea is severe and persistent at 6 weeks post-escalation at a stable dose, that warrants medical attention. If it has been 2 weeks since a dose increase and nausea is significant but improving, the expected trajectory suggests it will continue to improve. Distinguishing "I have been nauseous for 2 weeks after my dose increase" from "I have been nauseous for 6 weeks at a stable dose" changes the clinical response.

2. Constipation management requires the two-component approach

GLP-1 receptor agonists slow colonic transit independently of dietary fiber intake — this is a direct pharmacodynamic effect on enteric GLP-1 receptors in the colon. Unlike nausea, this effect does not fully resolve with dose habituation; it persists throughout treatment in most patients. The 2023 obesity surgery and GLP-1 GI complication review in Obesity Surgery identifies the two-component approach as most effective: (1) osmotic agent such as polyethylene glycol (MiraLax) for acute relief, and (2) proactive dietary fiber at 25–35 g/day to prevent recurrence. Stimulant laxatives (senna, bisacodyl) work for acute episodes but are not appropriate for long-term daily use on GLP-1 therapy. Patients who try to manage constipation with stimulant laxatives only tend to report cycling between constipation and diarrhea — a pattern that fiber and osmotic agents avoids.

3. Fatigue in the first 4–12 weeks has a specific and underappreciated cause

Fatigue is reported by 5–11% of GLP-1 trial participants and is rarely discussed in patient education materials compared to nausea. The mechanism in most cases is not the medication itself — it is caloric restriction driven by appetite suppression. When appetite drops sharply in the first weeks on a GLP-1, many patients eat 600–900 kcal/day without intending to, which produces fatigue through inadequate carbohydrate and protein intake rather than a direct drug effect. Patients who deliberately maintain caloric intake above 1,000 kcal/day during early titration, even when not hungry, report substantially less fatigue. This is a dietary intervention, not a medication management one. True drug-related fatigue — rare, and sometimes associated with hypoglycemia in diabetic patients on concurrent insulin — is distinguishable by its onset pattern and association with low blood glucose readings.

What this means for day-to-day side effect management

The most effective approach to GLP-1 side effects combines three elements: (1) slow the titration schedule if side effects are interfering with daily function — this is within label and clinically appropriate; (2) treat constipation proactively with fiber and osmotic agents, not reactively with stimulant laxatives; (3) maintain caloric intake above 800 kcal/day even during periods of low appetite to prevent nutrition-driven fatigue. For a full list of foods that tend to worsen vs. improve GLP-1 nausea, see our nutrition guide. If any side effect requires you to visit an emergency room, contact your prescriber immediately — documentation of serious adverse events should go through the formal FDA MedWatch system.

Frequently Asked Questions

How long does nausea from a GLP-1 last?

Nausea typically peaks in the first 1–2 weeks after a dose increase and improves over 4–8 weeks at a stable dose. It is less likely to resolve at the starting dose and more likely to resolve once you have been at any given dose for 6+ weeks. Persistent severe nausea more than 8 weeks after reaching a stable dose is worth discussing with your prescriber — it may indicate the dose is above your personal tolerance ceiling.

What foods make GLP-1 nausea worse?

High-fat meals are the most consistently reported nausea trigger — fat strongly stimulates GLP-1 release and slows gastric emptying further. Spicy foods, alcohol, and large meal volumes also worsen nausea. Eating smaller, lower-fat meals more frequently, avoiding lying down immediately after eating, and avoiding carbonated beverages are the most commonly effective dietary adjustments.

Should I take anti-nausea medication with my GLP-1?

Over-the-counter options like ginger (in tea or capsule form) and vitamin B6 have modest evidence for nausea reduction and low risk. Prescription antiemetics (ondansetron, promethazine) can be prescribed for patients with severe nausea, though they are not routinely provided with GLP-1 prescriptions. Discuss with your prescriber if OTC options are insufficient — the goal is to keep you on the medication at a therapeutic dose, not to tough it out.

Why am I constipated on a GLP-1 and what can I do?

GLP-1 receptor agonists slow colonic motility as a direct pharmacodynamic effect. This does not fully resolve with dose habituation. Prevention is more effective than treatment: increase dietary fiber to 25–35 g/day (from food and/or psyllium supplementation), drink at least 2 liters of water daily, and maintain physical activity. For acute constipation, polyethylene glycol (MiraLax) is the recommended first-line treatment. Stimulant laxatives work short-term but are not appropriate for ongoing daily use.

Is hair loss a side effect of GLP-1 medications?

Hair loss (telogen effluvium) is not a direct pharmacological effect of GLP-1 medications but is commonly reported and is related to rapid weight loss and caloric restriction rather than the drug itself. Telogen effluvium is triggered by physiological stress — including significant caloric deficit — and typically begins 2–4 months after the stressor. It is usually temporary and self-resolving once weight loss stabilizes. Adequate protein intake (100+ g/day) reduces but does not eliminate this risk.

When should I call my doctor about a GLP-1 side effect?

Contact your prescriber promptly for: severe abdominal pain, especially if it radiates to the back (possible pancreatitis); persistent vomiting preventing oral hydration for more than 24 hours; yellowing of the skin or eyes (possible gallbladder or liver issue); rapid heart rate with dizziness; or any injection-site reaction with redness, warmth, and spreading tenderness (possible infection). These are uncommon but require evaluation — do not attempt to manage them with dietary changes or OTC medications alone.

Does taking my GLP-1 injection at a specific time of day reduce side effects?

Some patients report lower nausea when injecting in the evening, so that the peak pharmacodynamic effect coincides with sleep. No randomized trial has tested injection timing on side effect burden, so this is anecdotal but low-risk to try. Consistency of the day of the week matters more than time of day — semaglutide and tirzepatide are weekly injections and should be taken on the same day each week.

Sources

1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
2. Joshi SR, et al. "SURMOUNT-1: Tirzepatide for Obesity." NEJM, 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
3. FDA. "Ozempic (semaglutide) Prescribing Information." https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s012lbl.pdf
4. Lete I, Allué J. "The Effectiveness of Ginger in the Prevention of Nausea and Vomiting." Nutrition Journal, 2016. https://nutritionj.biomedcentral.com/articles/10.1186/1475-2891-13-20
5. Davies M, et al. "Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)." The Lancet, 2021. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00213-0/fulltext
6. Rubino D, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity." JAMA, 2021. https://jamanetwork.com/journals/jama/fullarticle/2777886